Dynactin: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: Dynactin

NCBI ID: P19799

Dynactin

Other Name(s): Microtubule-associated dynactin complex | Dynein activator complex

Dynactin: A Protein Target for Cancer and Neurodegenerative Diseases

Dynactin, also known as Microtubule-associated dynamactin complex, is a protein that plays a crucial role in the proper functioning of microtubules, which are essential components of the cytoskeleton in eukaryotic cells. Dynactin helps to regulate the movement of cells, particularly during mitosis and meiosis, and is essential for the formation and stability of mitotic spindles.

Recent studies have identified Dynactin as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. The high level of interest in Dynactin as a drug target is due to its ability to modulate the dynamics of microtubules and its involvement in several cellular processes that are associated with the development and progression of diseases.

One of the key reasons for the recent interest in Dynactin as a drug target is its ability to interfere with the dynamics of microtubules. Microtubules are dynamic structures that play a critical role in the regulation of cellular processes, including cell division, intracellular transport, and cell signaling. Dynactin is known to regulate the movement of microtubules and to influence the stability of these structures. This suggests that Dynactin may be a useful target for drugs that aim to disrupt microtubule dynamics and cause cellular dysfunction.

In addition to its role in regulating microtubule dynamics, Dynactin has also been shown to be involved in several other cellular processes that are associated with the development and progression of diseases. For example, Dynactin has been shown to be involved in the regulation of cell migration. , which is a critical process for the development of cancer. In addition, Dynactin has also been shown to be involved in the regulation of cell survival and in the development of neurodegenerative diseases.

Another promising aspect of Dynactin as a drug target is its involvement in several diseases that are currently uncurable. For example, Dynactin has been shown to be involved in the development of cancer, neurodegenerative diseases, and developmental disorders, which are some of the most significant diseases that affect human health. The recent identification of Dynactin as a potential drug target for these diseases makes it an important area of 鈥嬧?媟esearch for the development of new treatments.

In conclusion, Dynactin is a protein that plays a critical role in the regulation of microtubule dynamics and has been shown to be involved in several cellular processes that are associated with the development and progression of diseases. As a result, Dynactin has generated a significant level of interest as a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of Dynactin in these diseases and to develop new treatments.

Protein Name: Dynactin

The "Dynactin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Dynactin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets